Table 1:
Patient characteristics of the 3 study cohorts (SUVmax, RNAseq, and TMA). A substantial number of the patients in the RNAseq and TMA cohorts were also included in the SUVmax analysis. The p-values shown represent comparisons between patients included in both the RNAseq and SUVmax analysis versus patients included only in the SUVmax analysis to determine if the RNAseq subgroup was biasing the overall cohort (using the Fisher’s exact or Wilcoxon tests as appropriate). The same was done for the TMA subgroup.
| SUV Cohort | RNAseq Cohort | p-value | TMA Cohort | p-value | |
|---|---|---|---|---|---|
| All patients | 318 | 68 (57 in SUV cohort) | 82 (67 in SUV cohort) | ||
| Age at Diagnosis | 0.42 | 0.94 | |||
| Median (Range) | 50 (23–92) | 53 (25–81) | 52 (25–92) | ||
| FIGO Stage (%) | 0.52 | 0.26 | |||
| I | 125 (39.3 %) | 20 (29.4%) | 29 (35.4%) | ||
| II | 119 (37.4%) | 25 (36.8%) | 28 (34.1%) | ||
| III | 69 (21.7%) | 21 (30.9%) | 22 (26.8%) | ||
| IV | 5 (1.6%) | 2 (2.9%) | 3 (3.7%) | ||
| Lymph Node Involvement (%) | 0.08 | 0.82 | |||
| None | 146 (45.9%) | 33 (48.5%) | 40 (58.8%) | ||
| Pelvic | 122 (38.4%) | 21 (30.9%) | 27 (32.9%) | ||
| Para-aortic/supraclavicular | 50 (15.7%) | 14 (20.6%) | 15 (18.3%) | ||
| Histology | 0.85 | 0.86 | |||
| Squamous | 256 (80.5%) | 55 (80.9%) | 56 (80.5%) | ||
| Non-squamous | 62 (19.5%) | 13 (19.1%) | 16 (19.5%) | ||
| Adenocarcinoma | 42 (13.2%) | 9 (13.2%) | 10 (12.2%) | ||
| Small cell | 8 (2.5%) | 2 (2.9%) | 2 (2.4%) | ||
| Adenosquamous | 4 (1.3%) | 2 (2.9%) | 1 (1.2%) | ||
| Other | 8 (2.5%) | 0 | 3 (3.7%) | ||
| SUVmax | 0.65 | 0.19 | |||
| Mean (Range) | 14.6 (2.9 – 60.3) | 17.0 (3.4–53.6) | 15.4 (3.77–60.3) | ||